Related Experiment Videos
Gemcitabine in combination with new platinum compounds: an update
D R Gandara1, M J Edelman, P N Lara
1Division of Hematology/Oncology, University of California, Davis Cancer Center, Sacramento, California, USA.
Oncology (Williston Park, N.Y.)
|April 17, 2001
Summary
Gemcitabine combined with platinum analogs like carboplatin shows promise for advanced non-small-cell lung cancer. Modified dosing schedules improve efficacy and reduce toxicities, offering a better therapeutic index.
Area of Science:
- Oncology
- Medical Chemistry
Background:
- Cisplatin-gemcitabine regimens are active for advanced non-small-cell lung cancer (NSCLC).
- Carboplatin, a platinum analog, offers a better toxicity profile than cisplatin.
- Carboplatin may be equivalent to cisplatin in advanced NSCLC with improved therapeutic index via AUC dosing.
Purpose of the Study:
- To review recent studies on gemcitabine plus carboplatin combinations.
- To present preliminary data on gemcitabine with oxaliplatin.
Main Methods:
- Review of recent clinical trials and studies.
- Analysis of toxicity and efficacy data for gemcitabine-platinum analog combinations.
Main Results:
- Initial gemcitabine-carboplatin trials with days 1, 8, 15 dosing showed problematic thrombocytopenia.
- Modified 21-day schedules (gemcitabine on days 1 and 8) demonstrate improved efficacy and toxicity profiles.
- Carboplatin has replaced cisplatin in combination with paclitaxel for several tumor types due to its favorable toxicity.
Conclusions:
- Modified dosing of gemcitabine with carboplatin offers an improved therapeutic index for advanced NSCLC.
- Further investigation into gemcitabine-oxaliplatin combinations is warranted.